22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
19:13 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Melinta closes $123.2M follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $123.2 million through the sale of 24.6 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The figures include the sale of...
17:14 , May 24, 2018 |  BC Extra  |  Financial News

Melinta raises $110M in follow-on

Anti-infectives company Melinta Therapeutics Inc. (NASDAQ:MLNT) raised $110 million through the sale of 22 million shares at $5 in a follow-on underwritten by J.P. Morgan, Jefferies and Cantor Fitzgerald. The price is a 32% discount...
00:38 , Jan 31, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, Dragonfly

Ipsen Group (Euronext:IPN; Pink:IPSEY) appointed Sotirios Stergiopoulos CMO. He will continue to serve as SVP, head of global medical affairs. Cancer company Dragonfly Therapeutics Inc. (Cambridge, Mass.) hired Jean-Marie Cuillerot as CMO. He was CMO...
17:36 , Nov 2, 2017 |  BC Extra  |  Company News

Management tracks: Melinta, Lundbeck

Infectious disease company Melinta Therapeutics Inc. (New Haven, Conn.) hired Dan Wechsler as president and CEO and John Bluth as EVP of investor relations and corporate communications. Wechsler was operating partner at Welsh, Carson, Anderson...
14:46 , Aug 11, 2017 |  BC Week In Review  |  Company News

Melinta goes public by acquiring majority of Cempra

Melinta Therapeutics Inc. (New Haven, Conn.) has found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc. (NASDAQ:CEMP). The combined company will retain Melinta's name and will be...
21:30 , Aug 9, 2017 |  BC Extra  |  Company News

Melinta goes public by acquiring majority of Cempra

Melinta Therapeutics Inc. (New Haven, Conn.) has found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc. (NASDAQ:CEMP). The combined company will retain Melinta's name and will be...
00:19 , May 19, 2017 |  BC Week In Review  |  Clinical News

Cempra withdraws Solithera MAA

Cempra Inc. (NASDAQ:CEMP) withdrew an MAA for oral and IV formulations of Solithera solithromycin (CEM-101) to treat community-acquired bacterial pneumonia (CABP) after receiving EMA’s Day 120 questions. The company believes EMA will require additional data...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
17:41 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

Oral Solithera: Ph III SOLITAIRE-U data

Top-line data from the microbiological intent-to-treat (mITT) population of the first 262 patients with uncomplicated urogenital gonorrhea with or without concomitant chlamydia infection in the open-label, U.S. and Australian Phase III SOLITAIRE-U trial showed that...